Sandoz Group AG - Registered Shares SDZ

SWX: SDZ | ISIN: CH1243598427   27/06/2025
43,35 CHF (+0,95%)
(+0,95%)   27/06/2025

2 juni 2025 · Sandoz launches first and only interchangeable denosumab biosimilars in US, providing new affordable treatment options for over 10 million patients[1] · Persbericht

21 mei 2025 · Sandoz launches Pyzchiva® autoinjector, first commercially available in Europe for ustekinumab biosimilars · Persbericht

30 april 2025 · Sandoz reports Q1 2025 net sales in line with company expectations; full-year guidance confirmed · Persbericht

29 april 2025 · Sandoz enters global collaboration license agreement with Henlius to commercialize leading oncology therapy, ipilimumab, in multiple indications · Persbericht

15 april 2025 · Shareholders approve all resolutions proposed by Board of Directors at Annual General Meeting of Sandoz Group AG · Persbericht

14 april 2025 · [Corrected] Sandoz files antitrust litigation against Amgen regarding patient access to etanercept biosimilar in the US · Persbericht

14 april 2025 · Sandoz files antitrust litigation against Amgen regarding patient access to etanercept biosimilar in the US · Persbericht

31 maart 2025 · Sandoz strengthens its balance sheet by issuing new bonds to repay spin-off term loans, and signs new USD 2 billion revolving credit facility · Persbericht

5 maart 2025 · Sandoz reports strong FY 2024 results and Q4 2024 sales · Persbericht

24 februari 2025 · Sandoz launches biosimilar Pyzchiva® (ustekinumab-ttwe) in the US, offering new treatment for around 12 million patients[1-4] · Persbericht

3 februari 2025 · Francisco Ballester to retire; Peter Stenico appointed President Region International · Persbericht

14 januari 2025 · Sandoz to confirm strategic roadmap and highlight pipeline catalysts at 43rd Annual J.P. Morgan Healthcare Conference · Persbericht

17 december 2024 · Sandoz takes further steps to resolve legacy US Generic Drug Antitrust Class Action Litigation · Persbericht

15 november 2024 · Sandoz receives European Commission approval for Afqlir® (aflibercept), further strengthening leading biosimilar portfolio · Persbericht

30 oktober 2024 · Sandoz reports third-quarter and nine-month 2024 sales · Persbericht

Mijn selecties